Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Amsterdam  >  Kiadis Pharma N.V.    KDS   NL0011323407

KIADIS PHARMA N.V.

(KDS)
  Report  
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Euronext Amsterdam
09/10/2019 09/11/2019 09/12/2019 09/13/2019 09/16/2019 Date
5.62(c) 5.28(c) 5.47(c) 5.375(c) 5.37 Last
742 485 776 286 430 568 232 598 132 366 Volume
-8.62% -6.05% +3.60% -1.74% -0.09% Change
More quotes
Financials (EUR)
Sales 2019 -
EBIT 2019 -54,9 M
Net income 2019 -58,4 M
Debt 2019 0,40 M
Yield 2019 -
Sales 2020 1,27 M
EBIT 2020 -53,5 M
Net income 2020 -61,0 M
Finance 2020 39,7 M
Yield 2020 -
P/E ratio 2019 -2,37x
P/E ratio 2020 -2,58x
EV / Sales2019 -
EV / Sales2020 93,8x
Capitalization 159 M
More Financials
Company
Kiadis Pharma is developing potentially life saving therapies for patients with late-stage blood cancers, who are in need of a transplant, an area of significant need. Kiadis Pharma is building a fully integrated biopharmaceutical company to maximize the potential of ATIR, the company's proprietary... 
More about the company
Surperformance© ratings of Kiadis Pharma N.V.
Trading Rating : Investor Rating : -
More Ratings
Latest news on KIADIS PHARMA N.V.
09/10KIADIS PHARMA N : announces results for the six months ended June 30, 2019
AQ
08/19KIADIS PHARMA N : Announces Investor Events for September 2019
AQ
07/31KIADIS PHARMA N : to present at upcoming conference in August 2019
AQ
07/01KIADIS PHARMA : updates status of marketing authorization application for ATIR10..
AQ
06/28KIADIS PHARMA : updates status of marketing authorization application for ATIR10..
GL
06/24KIADIS PHARMA : Announces Results Annual General Meeting
GL
06/06KIADIS PHARMA : completes acquisition of CytoSen Therapeutics, Inc.
GL
06/04KIADIS PHARMA : to present at upcoming conferences in June 2019
AQ
06/03KIADIS PHARMA : to present at upcoming conferences in June 2019
AQ
06/01KIADIS PHARMA : raises c.EUR 28 million in a private placement of c.3.7 million ..
AQ
More news
Analyst Recommendations on KIADIS PHARMA N.V.
More recommendations
Sector news : Biotechnology & Medical Research - NEC
02:48aA Plan to Fight Hep C -- WSJ
DJ
09/03Novartis, Lonza deepen biosimilars push with MS, arthritis drug deals
RE
08/29GLOBAL MARKETS LIVE : Dell, United Airlines, UBS, Apple…
08/28U.S. judge rules for Regeneron, Sanofi in Amgen cholesterol drug patent fight
RE
08/28US Judge Mostly Sets Aside Jury Ruling on Repatha Patents -Reuters
DJ
More sector news : Biotechnology & Medical Research - NEC
Chart KIADIS PHARMA N.V.
Duration : Period :
Kiadis Pharma N.V. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends KIADIS PHARMA N.V.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 6
Average target price 12,50  €
Last Close Price 5,38  €
Spread / Highest target 291%
Spread / Average Target 133%
Spread / Lowest Target -6,98%
EPS Revisions
Managers
NameTitle
Arthur K. Lahr Chief Executive Officer
Mark A. Wegter Chairman-Supervisory Board
Jan Feijen Chief Operations Officer
Scott A. Holmes Chief Financial Officer
Andrew S. Sandler Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
KIADIS PHARMA N.V.-29.55%176
IQVIA HOLDINGS INC30.28%29 649
LONZA GROUP32.78%25 385
CELLTRION, INC.--.--%18 337
INCYTE CORPORATION20.19%16 438
EXACT SCIENCES CORPORATION69.11%13 817